975 results on '"Musolino Caterina"'
Search Results
52. Long-Term Results in Multiple Myeloma After High-Dose Melphalan and Autologous Transplantation According to Response Categories in the Era of Old Drugs
53. Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile
54. New orally active proteasome inhibitors in multiple myeloma
55. Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms
56. Targeting Redox Regulation as a Therapeutic Opportunity against Acute Leukemia: Pro-Oxidant Strategy or Antioxidant Approach?
57. Critical Role of Aquaporins in Cancer: Focus on Hematological Malignancies
58. Circulating Tumour Cells, Cell Free DNA and Tumour-Educated Platelets as Reliable Prognostic and Management Biomarkers for the Liquid Biopsy in Multiple Myeloma
59. Cold Atmospheric Plasma Targeting Hematological Malignancies: Potentials and Problems of Clinical Translation
60. Mast Cells and Vitamin D Status: A Clinical and Biological Link in the Onset of Allergy and Bone Diseases
61. MicroRNA Profiling in Asthma: Potential Biomarkers and Therapeutic Targets
62. Spontaneous Healing of Clodronate-Related Osteonecrosis of the Jaw
63. A population‐based study of chronic myeloid leukemia patients treated with imatinib in first line
64. Changes in advanced oxidation protein products, advanced glycation end products, and s-nitrosylated proteins, in patients affected by polycythemia vera and essential thrombocythemia
65. Evaluation of interleukin-23 plasma levels in patients with polycythemia vera and essential thrombocythemia
66. Harnessing Unconventional T Cells and Innate Lymphoid Cells to Prevent and Treat Hematological Malignancies: Prospects for New Immunotherapy
67. Epigenetic Crosstalk between Malignant Plasma Cells and the Tumour Microenvironment in Multiple Myeloma
68. New Insights into Neuropeptides Regulation of the Immune System and Hemopoiesis: Effects on Hematologic Malignancies
69. Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment
70. Exosome-Mediated Therapeutic Strategies for Management of Solid and Hematological Malignancies
71. Circular RNA as a Novel Biomarker for Diagnosis and Prognosis and Potential Therapeutic Targets in Multiple Myeloma
72. Modulation of Cellular Redox Parameters for Improving Therapeutic Responses in Multiple Myeloma
73. Specialized Intercellular Communications via Tunnelling Nanotubes in Acute and Chronic Leukemia
74. Machine Learning and Deep Learning Applications in Multiple Myeloma Diagnosis, Prognosis, and Treatment Selection
75. Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia
76. Prospective validation of predictive value of abdominal computed tomography scan on time to first treatment in Rai 0 chronic lymphocytic leukemia patients: results of the multicenter O-CLL1-GISL study
77. 636 Global cardiovascular assessment in patients with PH+ chronic myeloid leukaemia treated with TKI: long-term follow-up
78. Secondary Immunodeficiency in Hematological Malignancies: Focus on Multiple Myeloma and Chronic Lymphocytic Leukemia
79. Multiple Myeloma Cell-Derived Exosomes: Implications on Tumorigenesis, Diagnosis, Prognosis and Therapeutic Strategies
80. OAB-055: Gain and amplification of 1q induce transcriptome deregulation and worsen the outcome of newly diagnosed Multiple Myeloma patients
81. Effect of therapeutic plasma exchange on plasma levels of oxidative biomarkers in a patient with thrombotic thrombocytopenic purpura
82. Is ZAP70 still a key prognostic factor in early stage chronic lymphocytic leukaemia? Results of the analysis from a prospective multicentre observational study
83. Phage-Phenotype Imaging of Myeloma Plasma Cells by Phage Display
84. Involvement of Alarmins in the Pathogenesis and Progression of Multiple Myeloma
85. Immune thrombocytopenia
86. Global cardiovascular assessment in patients with PH+ chronic myeloid leukaemia treated with TKI: long-term follow-up
87. Increase of novel biomarkers for oxidative stress in patients with plasma cell disorders and in multiple myeloma patients with bone lesions
88. Impact of Gain and Amplification of 1q in Newly Diagnosed Multiple Myeloma Patients Receiving Carfilzomib-Based Treatment in the Forte Trial
89. Prospective validation of a risk score based on biological markers for predicting progression free survival in Binet stage A chronic lymphocytic leukemia patients: Results of the multicenter O-CLL1-GISL study
90. High-throughput sequencing for the identification of NOTCH1 mutations in early stage chronic lymphocytic leukaemia: biological and clinical implications
91. MiRNome expression is deregulated in the peripheral lymphoid compartment of multiple myeloma
92. Reduction in IL-33 Plasma Levels Might Be Involved in T Cell Dysregulation in Chronic Lymphocytic Leukemia
93. Pros and Cons of the Cannabinoid System in Cancer: Focus on Hematological Malignancies
94. Reviewing the Significance of Vitamin D Substitution in Monoclonal Gammopathies
95. New Insights into YES-Associated Protein Signaling Pathways in Hematological Malignancies: Diagnostic and Therapeutic Challenges
96. Concentration of circulating endothelial progenitor cells (EPC) in normal pregnancy and in pregnant women with diabetes and hypertension
97. Promising Anti-Mitochondrial Agents for Overcoming Acquired Drug Resistance in Multiple Myeloma
98. Quantitative polymerase Chain reaction profiling of microRNAs in peripheral lymph-monocytes from MGUS subjects
99. Diagnostic utility of Sudoscan for detecting bortezomib-induced painful neuropathy: a study on 18 patients with multiple myeloma
100. Familial B-cell Chronic Lymphocytic Leukemia in a Population of Patients from Southern Italy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.